Evidence map›Paper›PMID 39934993›Full record

ReviewJournal of paediatrics and child health2025

Recent Advances in Diagnostics and Therapeutics for Paediatric Thyroid Cancer.

Joel A Vanderniet, Noemi A Fuentes-Bolanos, Yoon Hi Cho, David K V Chung, Gideon Sandler, Ali Moghimi, Bhavna Padhye, Kathy Tucker, Antoinette Anazodo, Paul Z Benitez-Aguirre

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of paediatrics and child health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Joel A VandernietSydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-7063-6667
Noemi A Fuentes-BolanosKids Cancer Centre, Sydney Children's Hospital, Randwick, New South Wales, Australia.
Yoon Hi ChoSydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-6568-8991
David K V ChungSydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Gideon SandlerSydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Ali MoghimiSydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-9578-2612
Bhavna PadhyeSydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Kathy TuckerSchool of Clinical Medicine, UNSW Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia.
Antoinette AnazodoSchool of Clinical Medicine, UNSW Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia.
Paul Z Benitez-AguirreSydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-7687-2898

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewPaediatric thyroid cancer management traditionally relied on extrapolation from adult data and, despite good survival outcomes, often involved extensive surgical approaches and radioactive iodine (RAI) therapy with potentially life-long complications. Increasing understanding of paediatric diagnostic techniques, molecular tumour drivers and targeted therapies will allow a more nuanced, disease-specific comprehensive model of care. This review summarises recent developments in paediatric thyroid cancer biology, diagnosis and models of care.

methodsReview of relevant literature from the last 5 years to inform a narrative summary by a multidisciplinary team of clinician experts in paediatric thyroid cancer management.

findingsStandardised risk scoring systems will likely improve the objectivity and accuracy of paediatric thyroid nodule risk stratification on ultrasound, but further studies are needed to validate these. Identification of somatic and germline gene variants is playing a rapidly increasing role in paediatric thyroid cancer diagnosis and planning of surgical approaches and neoadjuvant and adjuvant therapies. There is growing recognition that lobectomy may achieve comparable outcomes, with reduced risk of complications, to total thyroidectomy in patients with low-risk disease. Molecularly targeted therapies are now available for the management of advanced disease as an adjuvant, and likely neo-adjuvant, therapy for medical debulking of large tumours and resensitisation of RAI-resistant disease.

conclusionsThe management pathways for paediatric thyroid cancer are rapidly evolving due to the increasing availability of paediatric-specific data. As management options become more complex, interdisciplinary collaboration and shared decision-making are ever more important.

Indexed as

Thyroid NeoplasmsChildHumansThyroidectomymolecularly targeted therapymultidisciplinaryultrasound

Identifiers

PMID39934993
PMCPMC12053232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.